Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Micturition Reflex01:26

The Micturition Reflex

3.2K
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
3.2K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

809
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
809
Urinary Bladder01:23

Urinary Bladder

3.9K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
3.9K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.5K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bacillus Calmette-Guérin therapy in the management of upper tract urothelial carcinoma in-situ: a systematic review.

Translational andrology and urology·2026
Same author

Assessing the urologist workforce in British Columbia Wait times, workload, and burnout in 2022.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2026
Same author

Patient needs and preferences for a kidney stone self-monitoring app: a pilot survey analysis.

Urolithiasis·2026
Same author

Performance of percutaneous core biopsy in predicting renal tumour pathology: a systematic review.

BJU international·2025
Same author

Urethral Bulking Agent as a Salvage Procedure for Female Stress Urinary Incontinence: A Systematic Review and Meta-Analysis.

International urogynecology journal·2025
Same author

The use of intradetrusor botulinum toxin in the geriatric population.

BJUI compass·2025

Related Experiment Video

Updated: Mar 5, 2026

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.4K

Sacral neuromodulation for detrusor hyperactivity with impaired contractility.

Derek B Hennessey1, Nathan Hoag2, Johan Gani1

  • 1Department of Urology, Austin Hospital, Heidelberg, Victoria, Australia.

Neurourology and Urodynamics
|March 28, 2017
PubMed
Summary

Sacral neuromodulation (SNM) effectively treats detrusor hyperactivity with impaired contractility (DHIC), improving storage symptoms and voiding function. This study shows SNM offers satisfactory success rates for this challenging condition.

Keywords:
DHICdetrusor hyperactivity with impaired contractilitydetrusor overactivitysacral neuromodulation

More Related Videos

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.9K
A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling
06:36

A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

Published on: November 28, 2019

7.7K

Related Experiment Videos

Last Updated: Mar 5, 2026

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.4K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.9K
A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling
06:36

A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

Published on: November 28, 2019

7.7K

Area of Science:

  • Urology
  • Neurourology
  • Pelvic Floor Disorders

Background:

  • Detrusor hyperactivity with impaired contractility (DHIC) presents significant management challenges.
  • Sacral neuromodulation (SNM) is recognized for treating individual DHIC components, but outcomes for the combined condition were previously unreported.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of sacral neuromodulation (SNM) in patients diagnosed with detrusor hyperactivity with impaired contractility (DHIC).

Main Methods:

  • A prospective study followed 20 patients undergoing SNM for DHIC from April 2013 to October 2016.
  • Data collected included demographics, bladder diaries, subjective response rates, and validated questionnaires (ICIQ-OAB, PGI-I).
  • Success was defined by >50% improvement in storage symptoms and voided volume or reduced post-void residual (PVR) volumes.

Main Results:

  • 70% of patients (14/20) showed a significant treatment response to SNM for DHIC.
  • 60% (12/20) proceeded to implantable pulse generator (IPG) insertion, with 91.7% still using SNM at a mean follow-up of 17 months.
  • Statistically significant improvements were observed in voided volume (P=.016), PVR (P=.0296), ICIQ-OAB score (P<.0001), and ICIQ-OAB bother score (P=.016).

Conclusions:

  • This is the first study reporting outcomes of SNM for DHIC, demonstrating its effectiveness.
  • SNM is associated with satisfactory success rates in managing both detrusor hyperactivity and impaired contractility.
  • SNM offers a viable treatment option for patients with the complex condition of DHIC.